3D Markers
Shaping the Future
BioZorb® 3D Bioabsorbable Marker
The BioZorb® is a 3D implantable marker that consists of a spiral, bioabsorbable framework embedded with 6 permanent, titanium clips designed to precisely mark your surgical excision site. Designed to improve outcomes in Breast Conserving Surgery and absorb into the body over several years, the BioZorb provides 3-dimensional targeting for radiation therapy and comes in a range of sizes from 2-5cm including Lower Profile (LP). Available in Low Profile (LP) designed for smaller, flatter surgical cavities.
Visualize the Difference
- Cosmetic results: BioZorb marker has been shown in a case series to yield good/excellent cosmetic outcomes for at least 2 years post-surgery1
- Radiation: 96% radiation oncologists reported “improved accuracy” in setup & boost targeting in a prospective registry of 337 patients2
- Mammography: A published case series has shown minimal scarring after breast conservation therapy using BioZorb to mark the site3
- Radiation oncologists perceived they had “improved accuracy” in follow-up medical procedure, suggesting increased confidence through the use of BioZorb marker2
- In 92% of cases radiation oncologists verified as “easily seen” on CT2
- In 90% of patients, physicians have rated comesis good/excellent2
Permanent surgical site marking
References
- N = 20. Kaufman CS, et al. Long Term Value of 3-D Bioabsorbable Tissue Marker on Radiation Planning & Targeting, Cosmesis and Follow-up Imaging. Poster presented at the American Society of Breast Surgeons 17th Annual Meeting, April 27 – 30, 2017
- N = 337 patients prospectively followed through a registry.
Kaufman CS, et al. Registry Study of 337 Bio-Absorbable 3-D Implants Marking Lumpectomy Cavity Benefit Cosmesis While Targeting Radiation. Poster presented at the Society of Surgical Oncology Annual Cancer Conference March 15-17, 2017. - N = 110, single site prospective
Harms S, et al. Mammographic imaging after partial breast reconstruction: Impact of a bioabsorbable breast implant. J Clin Oncol 33, 2015 (suppl 28S; abstr 111)